S'abonner

Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis - 30/03/13

Doi : 10.1016/j.jaci.2013.01.011 
Sangil Lee, MD a, Erik P. Hess, MD a, David M. Nestler, MD a, Venkatesh R. Bellamkonda Athmaram, MD a, M. Fernanda Bellolio, MD a, Wyatt W. Decker, MD a, James T.C. Li, MD, PhD b, John B. Hagan, MD b, Veena Manivannan, MBBS a, Samuel C. Vukov, BS a, Ronna L. Campbell, MD, PhD a,
a Department of Emergency Medicine, Mayo Clinic, Rochester, Minn 
b Division of Allergic Diseases, Mayo Clinic, Rochester, Minn 

Corresponding author: Ronna L. Campbell, MD, PhD, Department of Emergency Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Abstract

Background

Risk factors for increased anaphylaxis severity are poorly understood. Angiotensin-converting enzyme (ACE) inhibitors have been associated with severe anaphylactic reactions in patients with hymenoptera venom allergy. Studies evaluating the association between beta-blockers and severe anaphylaxis have been conflicting.

Objective

To evaluate the association between antihypertensive medication use and increased anaphylaxis severity.

Methods

We included emergency department anaphylaxis patients aged 18 years and older. Markers of severe anaphylaxis were defined as (1) syncope, hypotension, or hypoxia; (2) signs and symptoms involving 3 or more organ systems; and (3) hospitalization. Antihypertensive medications evaluated included beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics. Simple and multiple logistic regression analyses were conducted to estimate the association between antihypertensive medication use and markers of increased anaphylaxis severity.

Results

Among 302 patients with anaphylaxis, 55 (18%) had syncope, hypoxia, or hypotension, 57 (19%) required hospitalization, and 139 (46%) had 3 or more organ system involvement. After adjusting for age, gender, suspected trigger, and preexisting lung disease, beta-blocker, ACE-inhibitor, diuretic, or antihypertensive medication use in aggregate remained associated with both 3 or more organ system involvement and need for hospital admission. The adjusted associations between antihypertensive medication use in aggregate and 3 or more organ system involvement yielded an odds ratio of 2.8 (95% CI, 1.5-5.2; P = .0008) and with hospitalization an odds ratio of 4.0 (95% CI, 1.9-8.4; P = .0001).

Conclusions

In emergency department anaphylaxis patients, antihypertensive medication use is associated with increased organ system involvement and increased odds of hospital admission, independent of age, gender, suspected trigger, or preexisting lung disease.

Le texte complet de cet article est disponible en PDF.

Key words : Anaphylaxis, antihypertensive medications, angiotensin-converting enzyme inhibitor, beta-blocker, risk factors, emergency department

Abbreviations used : ACE, CCB, ED, NIAID/FAAN, OR, SBP


Plan


 This publication was supported by National Institutes of Health/NCRR/NCATS CTSA grant no. UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
 Disclosure of potential conflict of interest: S. Lee, E. P. Hess, D. M. Nestler, V. R. Bellamkonda Athmaram, M. F. Bellolio, W. W. Decker, V. Manivannan, S. C. Vukov, and R. L. Campbell have received research support from the National Institutes of Health (NIH). J. T. C. Li has received research support from the NIH and has stock options in Novartis, Abbott, and Johnson & Johnson. J. B. Hagan has received research support from the NIH, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, and MedImmune; was chairman of the Dyax Adjudication panel of KALBITOR; and has held stock in Johnson & Johnson and TEVA in the last 3 years.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 131 - N° 4

P. 1103-1108 - avril 2013 Retour au numéro
Article précédent Article précédent
  • Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin
  • Laurence Pellerin, Julie Henry, Chiung-Yueh Hsu, Stéfana Balica, Catherine Jean-Decoster, Marie-Claire Méchin, Britta Hansmann, Elke Rodriguez, Stefan Weindinger, Anne-Marie Schmitt, Guy Serre, Carle Paul, Michel Simon
| Article suivant Article suivant
  • Vitamin D insufficiency is associated with challenge-proven food allergy in infants
  • Katrina J. Allen, Jennifer J. Koplin, Anne-Louise Ponsonby, Lyle C. Gurrin, Melissa Wake, Peter Vuillermin, Pamela Martin, Melanie Matheson, Adrian Lowe, Marnie Robinson, Dean Tey, Nicholas J. Osborne, Thanh Dang, Hern-Tze Tina Tan, Leone Thiele, Deborah Anderson, Helen Czech, Jeeva Sanjeevan, Giovanni Zurzolo, Terence Dwyer, Mimi L.K. Tang, David Hill, Shyamali C. Dharmage

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.